Q1 Earnings Estimate for MRKR Issued By HC Wainwright

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Marker Therapeutics in a research report issued on Friday, March 20th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Marker Therapeutics’ Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.30) EPS and FY2030 earnings at ($0.75) EPS.

Other equities analysts have also issued reports about the stock. Zacks Research lowered shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.25.

Marker Therapeutics Stock Down 3.8%

Shares of NASDAQ MRKR opened at $1.26 on Monday. Marker Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.07. The business’s 50 day moving average price is $1.57 and its 200 day moving average price is $1.31. The firm has a market cap of $21.00 million, a P/E ratio of -1.48 and a beta of 1.42.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.17. Marker Therapeutics had a negative return on equity of 80.86% and a negative net margin of 343.03%.The firm had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $0.68 million.

Institutional Investors Weigh In On Marker Therapeutics

Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the 3rd quarter valued at about $25,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics during the third quarter worth approximately $33,000. Jane Street Group LLC purchased a new position in Marker Therapeutics during the second quarter worth approximately $33,000. Boyer Financial Services Inc. acquired a new stake in Marker Therapeutics in the fourth quarter valued at approximately $57,000. Finally, XTX Topco Ltd grew its holdings in Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after purchasing an additional 36,269 shares during the period. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.